Waters Corporation’s newly built Precision Chemical Manufacturing Facility in Taunton has achieved LEED certification. The products manufactured at this facility are essential for thousands of laboratories that ensure the quality and safety of medicines, food and water for millions of people worldwide. Waters’ Taunton site is the first and only LEED-certified chemical manufacturing facility in […]

Ascidian Therapeutics has launched with a $50 million Series A financing from life sciences venture capital firm ATP. With a focus on treating human diseases by replacing mutated exons at the RNA level, Ascidian’s technology enables therapeutic targeting of large genes and genes with high mutational variance while maintaining native gene expression patterns and levels. […]

Odyssey Therapeutics has raised $168 million in a Series B financing following its $218 million Series A in December 2021, bringing the total capital raised to $386 million. The funding will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines. “Odyssey is pioneering next generation therapeutics by marrying a powerful drug discovery […]

Palleon Pharmaceuticals scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry. Waltham-based Palleon is a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases. The award reflects Dr. Bertozzi’s deep contributions not only to chemistry but to biology and medicine, including the foundational science underlying Palleon’s first-in-class, […]

Cambridge-based Amylyx Pharmaceuticals has won FDA approval for Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease. Relyvrio significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. Relyvrio can be taken as a monotherapy or with existing approved treatments. ALS is […]

Partners Eisai and Biogen announced positive topline results from Eisai’s Phase 3 clinical trial of lecanemab, an investigational drug for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease. Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results. Eisai plans to discuss the data with regulatory authorities […]